文献速递肝病

慢性丁型肝炎自然病程中四分之一患者HDV-RNA下降或转阴

One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-28

研究采用WHO国际标准定量检测56例未治疗慢性丁型肝炎患者连续血清样本,平均随访5.6年。25%患者HDV-RNA下降≥2log10,20%自发转阴;下降组HBsAg降幅更大,ALT和HBV-DNA随时间下降,但临床结局无组间差异。

要点

  • 未治疗CHD患者平均随访5.6年,25%出现HDV-RNA下降≥2log10,20%自发转阴
  • HDV-RNA下降≥2log10者HBsAg降幅显著大于下降<2log10者
  • ALT和HBV-DNA总体随时间下降,但临床结局无组间差异

核心结论

  • 四分之一未治疗CHD患者在平均5.6年随访中HDV-RNA下降≥2log10,20%达到HDV-RNA检测不到。
  • HDV-RNA下降与ALT降低相关,对设计CHD新疗法有启示。

研究设计与样本

  • 连续纳入56例HDV-RNA可检测的CHD患者,回顾性检测323份血清样本。
  • 采用敏感技术及首个WHO国际HDV-RNA标准定量HDV-RNA,同时检测HBsAg、HBV-DNA和HBV-RNA。
  • 患者随访>3年,平均随访5.6(3-16)年。

主要发现

  • 14例(25%)出现≥2log10 HDV-RNA下降,其中11例(20%)自发HDV-RNA检测不到。
  • 4例(7%)HBsAg消失且HDV-RNA检测不到,其余42例(75%)HDV-RNA持续可检测。
  • HDV-RNA下降≥2log10组HBsAg降幅为-0.7±1.1 log IU/mL,下降<2log10组为-0.09±0.9 log IU/mL(P=0.039)。
  • ALT和HBV-DNA水平总体随时间下降,两组临床结局无差异。

关键数值与推荐

  • 基线中位HDV-RNA为5.3(4.2-6.5)log10 IU/mL。
  • 基线中位HBsAg为4.0(3.5-4.3)log10 IU/mL,中位HBV-DNA为1.6(1.0-2.6)log10 IU/mL。
  • 基线ALT正常者13例(23%)。
  • HBeAg阴性者占82%,肝硬化者近半,64%正在接受核苷(酸)类似物治疗。

临床怎么用

  • 对未治疗CHD患者应定期监测HDV-RNA和ALT,认识自发HDV-RNA下降或转阴的可能。
  • HDV-RNA下降≥2log10与HBsAg下降更多相关,可作为评估疾病活动及治疗应答的参考指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spontaneous HDV-RNA fluctuations, assessed by nonstandardised in-house assays, have been reported during the course of chronic hepatitis delta (CHD). AIMS: To evaluate changes in serum HDV-RNA concentrations in untreated CHD patients and correlate these changes with other HBV markers. METHODS: A total of 323 consecutive serum samples from 56 CHD patients (detectable HDV-RNA) followed for >3 years were retested for HDV-RNA levels by a sensitive technique using the first WHO international HDV-RNA standard. Quantitative HBsAg, HBV-DNA, and HBV-RNA were also determined. RESULTS: Most participants were male, middle-aged, white European, and HBeAg-negative (82%). Almost half had liver cirrhosis and 64% were receiving nucleos(t)ide analogues. At inclusion, median-HDV-RNA was 5.3 (4.2-6.5) log10 IU/mL, HBsAg 4.0 (3.5-4.3) log10 IU/mL, and HBV-DNA 1.6 (1.0-2.6) log10 IU/mL; ALT values were normal in 13 (23%). During a mean follow-up of 5.6 (3-16) years, 14 (25%) showed ≥2log10 HDV-RNA decline, including 11 (20%) who spontaneously achieved undetectable HDV-RNA. Four patients (7%) lost HBsAg, with undetectable HDV-RNA. The remaining 42 (75%) had persistently detectable HDV-RNA. During follow-up, patients with a ≥2log10 HDV-RNA decline showed a greater HBsAg drop (-0.7 ± 1.1 vs -0.09 ± 0.9 log IU/mL; P = 0.039) than those with a <2 log10 HDV-RNA decline. Overall, ALT and HBV-DNA levels decreased over time. There were no differences in clinical outcomes between groups. CONCLUSIONS: One-quarter of untreated CHD patients showed a ≥2log10 decline in HDV-RNA and 20% reached HDV-RNA undetectability during a mean follow-up of 5.6 years. The decline was associated with ALT decrease. These findings have implications for designing new therapies for CHD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Palom A, Sopena S, Riveiro-Barciela M, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. Aliment Pharmacol Ther. 2021. PMID: 34181772. doi:10.1111/apt.16485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。